

# **Palliative Coverage Drug Benefit Supplement**

**Effective April 1, 2021**



Inquiries should be directed to:

**Pharmacy Services**

Alberta Blue Cross  
10009 108 Street NW  
Edmonton AB T5J 3C5

Telephone Number: (780) 498-8370 (Edmonton)  
(403) 294-4041 (Calgary)  
1-800-361-9632 (Toll Free)

FAX Number: (780) 498-8384  
1-877-828-4106 (Toll Free)

**Website:**

<https://www.alberta.ca/palliative-care-health-benefits.aspx>

Administered by Alberta Blue Cross on behalf of Alberta Health.

The Drug Benefit List (DBL) is a list of drugs for which coverage may be provided to program participants. The DBL is not intended to be, and must not be used as a diagnostic or prescribing tool. Inclusion of a drug on the DBL does not mean or imply that the drug is fit or effective for any specific purpose. Prescribing professionals must always use their professional judgment and should refer to product monographs and any applicable practice guidelines when prescribing drugs. The product monograph contains information that may be required for the safe and effective use of the product.

Copies of the *Alberta Drug Benefit List* Publication are available from Pharmacy Services, Alberta Blue Cross at the address shown above.

*Changes may be made, without notice, to the List/Supplement through the on-line interactive List/Supplement, and any such changes to the on-line interactive List/Supplement are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.*

Please visit <https://www.alberta.ca/palliative-care-health-benefits.aspx> for the most current Palliative Coverage Drug Benefit Supplement information.

## Table of Contents

---

### PALLIATIVE COVERAGE DRUG BENEFIT SUPPLEMENT

#### SECTION 1 - INTRODUCTION AND THERAPEUTIC CLASSIFICATION OF DRUGS

##### Introduction

Eligibility .....	1.1
Price Policy .....	1.1
Interchangeable Drug Products .....	1.1
Excluded Special Authorization Drug Products .....	1.2

##### Pharmacologic-Therapeutic Classification of Drugs

10:00 Antineoplastic Agents.....	1
28:00 Central Nervous System Drugs .....	1
40:00 Electrolytic, Caloric, and Water Balance.....	1
56:00 Gastrointestinal Drugs.....	2
72:00 Local Anesthetics .....	3

#### APPENDICES

<b>Appendix 1</b> - Pharmaceutical Manufacturers.....	4
<b>Appendix 2</b> - Alphabetical List of Pharmaceutical Products .....	N/A
<b>Appendix 3</b> - Numerical List by Drug Identification Number .....	N/A

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

# SECTION 1

## Introduction and Therapeutic Classification of Drugs

# INTRODUCTION

## Eligibility

---

Benefits for *Palliative Coverage* are defined by the *Alberta Drug Benefit List* and the *Palliative Coverage Drug Benefit Supplement* (which defines select hydrating agents, laxatives and other products as additional benefits).

In order for patients to be eligible for *Palliative Coverage*, an application for the *Palliative Coverage Program* must be completed and signed by both the patient (or guardian) and the physician. This *Palliative Coverage Program* application form must be forwarded to Alberta Health for their consideration and approval.

## Price Policy

---

The [Price Policy](#) is stated in the *Alberta Drug Benefit List*.

## Interchangeable Drug Products

---

A box containing an X () to the left of the DIN or Product Identification Number (PIN) indicates that the product is **not** interchangeable with other products or interchangeability has not been assessed within the category. Refer to Policies and Guidelines Section 1 of the current *Alberta Drug Benefit List* for further information regarding interchangeable drug products.

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

## Excluded Special Authorization Drug Products

---

The following drug product(s) are listed in the special authorization section (Section 3) of the Alberta Drug Benefit List, however, special authorization coverage for these drug product(s) cannot be considered for those patients with Palliative Coverage:

Trade Name / Strength / Form	Generic Description	DIN	MFR
FULPHILA (0.6 ML SYRINGE) 6 MG / SYRINGE INJECTION	PEGFILGRASTIM	00002484153	BGP
GRASTOFIL 0.3 MG / SYRINGE INJECTION	FILGRASTIM	00002441489	APX
GRASTOFIL 0.48 MG / SYRINGE INJECTION	FILGRASTIM	00002454548	APX
LAPELGA (0.6 ML SYRINGE) 6 MG / SYRINGE INJECTION	PEGFILGRASTIM	00002474565	APX

### Excluded Criteria:

"In patients with non-myeloid malignancies, receiving myelosuppressive anti-neoplastic drugs with curative intent, to decrease the incidence of infection, as manifested by febrile neutropenia."

# Pharmacologic – Therapeutic Classification of Drugs

**10:00 ANTINEOPLASTIC AGENTS**

10:00

**MEGESTROL ACETATE**

**40 MG ORAL TABLET**

00002195917 MEGESTROL AAP \$ 1.4290

**160 MG ORAL TABLET**

00002195925 MEGESTROL AAP \$ 6.2293

**28:00 CENTRAL NERVOUS SYSTEM AGENTS**

28:08.08 ANALGESICS AND ANTIPYRETICS  
(OPIATE AGONISTS)

**FENTANYL**

**12 MCG/HR TRANSDERMAL PATCH**

00002341379 PMS-FENTANYL MTX PMS \$ 2.2280

00002327112 SANDOZ FENTANYL PATCH SDZ \$ 2.2280

00002311925 TEVA-FENTANYL TEV \$ 2.2280

**25 MCG/HR TRANSDERMAL PATCH**

00002341387 PMS-FENTANYL MTX PMS \$ 3.6560

00002327120 SANDOZ FENTANYL PATCH SDZ \$ 3.6560

00002282941 TEVA-FENTANYL TEV \$ 3.6560

**50 MCG/HR TRANSDERMAL PATCH**

00002341395 PMS-FENTANYL MTX PMS \$ 6.8820

00002327147 SANDOZ FENTANYL PATCH SDZ \$ 6.8820

00002282968 TEVA-FENTANYL TEV \$ 6.8820

**75 MCG/HR TRANSDERMAL PATCH**

00002341409 PMS-FENTANYL MTX PMS \$ 9.6800

00002327155 SANDOZ FENTANYL PATCH SDZ \$ 9.6800

00002282976 TEVA-FENTANYL TEV \$ 9.6800

**100 MCG/HR TRANSDERMAL PATCH**

00002341417 PMS-FENTANYL MTX PMS \$ 12.0500

00002327163 SANDOZ FENTANYL PATCH SDZ \$ 12.0500

00002282984 TEVA-FENTANYL TEV \$ 12.0500

**50 MCG / ML INJECTION**

00002240434 FENTANYL CITRATE SDZ \$ 2.7290

**40:00 ELECTROLYTIC, CALORIC, AND WATER BALANCE**

40:12 REPLACEMENT PREPARATIONS

**PARENTERAL SOLUTIONS (LARGE & SMALL VOL)**

**INJECTION**

00000990040 0.9% SODIUM CHLORIDE XXX \$ 0.0000

00000990034 3.3% DEXT/ 0.3% NACL (2/3-1/3) XXX \$ 0.0000

00000990037 3.3% DEXT/0.3% NACL/20 MEQ KCL XXX \$ 0.0000

00000990038 3.3% DEXT/0.3% NACL/40 MEQ KCL XXX \$ 0.0000

00000990033 5% DEXTROSE (D5W) XXX \$ 0.0000

00000990035 5% DEXTROSE/ 0.15% KCL 20 MEQ XXX \$ 0.0000

00000990036 5% DEXTROSE/ 0.3% KCL 40 MEQ XXX \$ 0.0000

00000990039 LACTATED RINGER'S XXX \$ 0.0000

**POTASSIUM CHLORIDE (K+)**

**149 MG / ML INJECTION**

00000037869 POTASSIUM CHLORIDE PFI \$ 0.4844



**40:00 ELECTROLYTIC, CALORIC, AND WATER BALANCE**

40:12 REPLACEMENT PREPARATIONS

**SODIUM CHLORIDE**

0.9 % INJECTION

00002304341	SODIUM CHLORIDE	TGT	\$	0.0998
00000037796	SODIUM CHLORIDE	PFI	\$	0.1860

**56:00 GASTROINTESTINAL DRUGS**

56:12 CATHARTICS AND LAXATIVES

**BISACODYL**

5 MG ORAL ENTERIC-COATED TABLET

00000254142	DULCOLAX	SAV	\$	0.1950
-------------	----------	-----	----	--------

10 MG RECTAL SUPPOSITORY

<input checked="" type="checkbox"/> 00002361450	BISACODYL	JPC	\$	0.4681
<input checked="" type="checkbox"/> 00000003875	DULCOLAX	SAV	\$	1.1800

**DOCUSATE CALCIUM**

240 MG ORAL CAPSULE

00002283255	JAMP-DOCUSATE CALCIUM	JPC	\$	0.0816
-------------	-----------------------	-----	----	--------

**DOCUSATE SODIUM**

100 MG ORAL CAPSULE

00002426838	DOCUSATE SODIUM	SNS	\$	0.0328
00000703494	PMS-DOCUSATE SODIUM	PMS	\$	0.0328
<input checked="" type="checkbox"/> 00000514888	SELAX	ODN	\$	0.0383
<input checked="" type="checkbox"/> 00000716731	DOCUSATE SODIUM	TAR	\$	0.0412
<input checked="" type="checkbox"/> 00001994344	SOFLAX	PMS	\$	0.0412
<input checked="" type="checkbox"/> 00002106256	COLACE	WSB	\$	0.1310

200 MG ORAL CAPSULE

00002029529	SOFLAX	PMS	\$	0.0920
-------------	--------	-----	----	--------

4 MG / ML ORAL SYRUP

00002086018	COLACE	WSB	\$	0.0220
00000870226	RATIO-DOCUSATE SODIUM	TEV	\$	0.0220
<input checked="" type="checkbox"/> 00000703508	PMS-DOCUSATE SODIUM	PMS	\$	0.0254

10 MG / ML ORAL DROPS

00002090163	COLACE	WSB	\$	0.1770
-------------	--------	-----	----	--------

**POLYETHYLENE GLYCOL 3350**

1 G / G ORAL POWDER

<input checked="" type="checkbox"/> 00002374137	EMOLAX	JPC	\$	0.0252
00002317680	LAX-A-DAY	PPH	\$	0.0503
00002346672	RELAXA	MPH	\$	0.0503

**SENNOSIDES**

8.6 MG ORAL TABLET

<input checked="" type="checkbox"/> 00080009595	JAMP-SENNA	JPC	\$	0.0604
<input checked="" type="checkbox"/> 00080009182	SENNOSIDES	JPC	\$	0.0604
<input checked="" type="checkbox"/> 00000896411	PMS-SENNOSIDES	PMS	\$	0.0633
<input checked="" type="checkbox"/> 00002068109	LAX-A SENNA	PPH	\$	0.0649
<input checked="" type="checkbox"/> 00000026158	SENOKOT	PUR	\$	0.0905

12 MG ORAL TABLET

<input checked="" type="checkbox"/> 00080009183	SENNOSIDES	JPC	\$	0.0709
<input checked="" type="checkbox"/> 00000896403	PMS-SENNOSIDES	PMS	\$	0.0746

1.7 MG / ML ORAL LIQUID

00080024394	JAMP SENNAQUIL	JPC	\$	0.0728
-------------	----------------	-----	----	--------

1.7 MG / ML ORAL SYRUP

00000367729	SENOKOT	PUR	\$	0.0485
-------------	---------	-----	----	--------

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

PALLIATIVE COVERAGE DRUG BENEFIT SUPPLEMENT

**56:00 GASTROINTESTINAL DRUGS**

56:12 CATHARTICS AND LAXATIVES

**SENNOSIDES/ DOCUSATE SODIUM**

8.6 MG \* 50 MG ORAL TABLET

00000026123 SENOKOT S

PUR

\$ 0.1840

---

**72:00 LOCAL ANESTHETICS**

72:00

**BUPIVACAINE HCL**

2.5 MG / ML INJECTION

00002443686 BUPIVACAINE

STM

\$ 0.4553

5 MG / ML INJECTION

00002443694 BUPIVACAINE

STM

\$ 0.5338

---

# APPENDICES

## Pharmaceutical Manufacturers

## Appendix 1

### Pharmaceutical Manufacturers

---

#### *A*

**AAP** AA Pharma Inc.

#### *J*

**JPC** Jamp Pharma Corporation

#### *M*

**MPH** Medexus Pharmaceuticals Inc

#### *O*

**ODN** Odan Laboratories Ltd.

#### *P*

**PFI** Pfizer Canada Inc.

**PMS** Pharmascience Inc.

**PPH** Pendopharm Inc.

**PUR** Purdue Pharma

#### *S*

**SAV** Sanofi-Aventis

**SDZ** Sandoz Canada Inc.

**SNS** Sanis Health Inc.

**STM** Sterimax Inc.

#### *T*

**TAR** Taro Pharmaceuticals Inc.

**TEV** Teva Canada Limited

**TGT** Teligent Canada, Inc.

#### *W*

**WSB** ANB Canada/Boyd Pharmaceuticals Inc.

#### *X*

**XXX** Miscellaneous Manufacturers

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.